About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

not long now lads

MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare Conference
JPMorgan 25th Annual Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN) today announced that Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA, will present at the JP Morgan 25th Annual Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2007 at 10:30 a.m. Pacific Standard Time. Mr. Moulder will provide an overview of the Company, its products, pipeline and 2007 corporate goals.

The presentation will be webcast live and may be accessed by logging on to our corporate website at www.mgipharma.com. Please connect to the Companys website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. An archived version of the presentation will be available through January 17, 2007.

About MGI PHARMA

MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leading biopharmaceutical company. MGI PHARMA markets Aloxi (palonosetron hydrochloride) Injection, Dacogen (decitabine) for Injection and Gliadel Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.

6 days to go to blast off

Not sure but I may of heard that before !!

i agree with potatohead there is something strange!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Err I think its what is called more sellers than buyers,hence the drop in price,nothing strange about that.
Makes a change from PH,news not out this afternoon,but in 6 days time.PH havent you got bored of ramping this share up??I guess one day you will get it right.
Anybodys guess when news comes,just hope its sooner rather than later,otherwise i see this share continuing to fall,still i guess those lucky enough to have some spare cash will be able to top up.

EiRx Therapeutics PLC
04 January 2007

EiRx Therapeutics plc ('EiRx' or 'the Company')



Placing


The Company announces that it has placed with clients of its broker, Ellis
Stockbrokers Limited, 250,000,000 EiRx Ordinary Shares of 0.2p nominal value at
a price of 0.2p per share to raise 500,000 before expenses. The funds raised
will be used to provide additional working capital for the Company.

Application has been made for the admission of these shares to trading on AIM
with admission expected to take place on 11 January 2007.

Following the issue of these shares, the total number of Ordinary Shares with
voting rights will be 2,975,743,260.


This information is provided by RNS
The company news service from the London Stock Exchange

Well one thing for sure PH does not have a

Luckypicker - 4 Jan'07 - 17:39 - 1053 of 1069


HERE YOU GO!!!

"john"
04/01/2007 16:56
To
cc

Subject
Re: Shareholder Question


There is very good and positive reasoning behind this move and the need to take dynamic decisions is one of the reasons we are no longer responding to individuals
Regards
John
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From:
Date: Thu, 4 Jan 2007 16:35:55
To:"John K Pool"
Subject: Fw: Shareholder Question


Dear John,

I am not very happy and I am sure many others are also not happy, re your
email below.

where is this significant news??

I think some explaining is needed here

Thanks






"John K Pool"
To

13/11/2006 17:14 cc

Subject
Re: Shareholder Question










We are looking at producing an analysts note currently We are not
considering going back to the market, if at all, without some very
significant news
John

tip off..get into GWP ...will go very high soon..sativex: drug with no harmful side effects

Whats even funnier ,is the fact most day PH predicts news,this time he didnt and sure enough news comes out-class.

One more time!!!! his name is not Potato Head but Dick Head!!!!

http://www.ptemag.com/pharmtecheurope/article/articleDetail.jsp?id=392072

THIS IS A GOOD READ

PER ERX RESULTS FORWARD LOOKING STATEMENT

We hope to continue to fund some of the desired development in the Company's
skill base through grant funding and partnering with Pharmaceutical majors. By
continuing to support the Company's development from compound discovery through
to the preclinical evaluation stage we believe that shareholder value will be
enhanced. The Company is open to exploring in-licensing and M&A options that
enable the acquisition of additional competences in medicinal chemistry and lead
optimisation, as and when the opportunity arises.

MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare Conference


MINNEAPOLIS--(BUSINESS WIRE)--Jan 3, 2007 - MGI Pharma, Inc. (Nasdaq:MOGN) today announced that Lonnie Moulder, President and Chief Executive Officer of MGI Pharma, will present at the JP Morgan 25th Annual Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2007 at 10:30 a.m. Pacific Standard Time. Mr. Moulder will provide an overview of the Company, its products, pipeline and 2007 corporate goals.

The presentation will be webcast live and may be accessed by logging on to our corporate website at www.mgipharma.com. Please connect to the Company's website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. An archived version of the presentation will be available through January 17, 2007.

Scientists find guardian gene's choices crucial to stopping cancer process
Save as PDF Print Email Blog It - +

Scientists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have uncovered a novel pathway by which the anti-cancer gene p53 springs into action, protecting a damaged cell from becoming cancer. The gene can either halt the cell's growth or send it spiraling toward certain death. How this choice is made, the researchers say, could have implications for future strategies in chemotherapy drug development.


According to Steven McMahon, Ph.D., associate professor of cancer biology at Jefferson Medical College, who led the work, the p53 gene's or rather its protein's ability to direct a damaged cell to either stop growing or commit suicide depends on turning on separate groups of target genes. He and his co-workers have found that after a cell's DNA is damaged, the p53 protein's ability to bind to the DNA can be affected.

Two enzymes, hMOF and TIP60, can chemically alter an amino acid, lysine 120, at the binding site, in turn influencing p53's decision on which target genes to turn on. The alteration can short-circuit p53's ability to cause the damaged cell to commit suicide, though it can still stop cell growth, suggesting that this change may help explain a mechanism behind p53's choice. They report their findings in the journal Molecular Cell.

"It's been known that p53 can induce cell cycle arrest or apoptosis (programmed cell death) as a way of eliminating developing cancer cells in response to cell damage, but no one has known how the choice is made," says Dr. McMahon. "This work narrows how the decision is made."

The findings could have implications for future drug development strategies. "Most chemotherapy strategies are aimed at getting cancer cells to die," Dr. McMahon says. "Figuring out what pathways p53 uses to cause that versus cell cycle arrest is important. It looks like this new modification that we have identified helps p53 make that decision."



"p53 is such an important player in the cancerous process it's nearly always mutated or inactivated in cancer that continuing to understand more about how it works will likely have significant implications for cancer research," says Dr. McMahon. "We wouldlike to understand the interplay between this newly identified pathway and others involved in p53 and cancer.

"Since p53 can make this decision, this might give some insight into which function of p53 is more important in which tissues," says co-author Stephen Sykes, a Ph.D. candidate at the University of Pennsylvania. "For example, K120 (lysine 120) mutations cause tumors in the prostate, but are not so much involved in causing immune system cancers such as lymphomas. That could suggest that p53's potential to cause cell death could be more important in certain tissues than in others. In the future, if someone could develop therapies that could specifically activate p53's potential to drive programmed cell death versus the cell cycle arrest potential, it might influence how a doctor might choose to treat a certain type of cancer.

"This may potentially enable the development of a cancer drug that would stimulate the enzymes to promote this modification driving p53 to apoptosis."

Over 9 million sold out today, only 19,000 I know, price has dropped off considerably over last couple of weeks, the spread has narrowed, only question now is how far will it fall. I reckon 0.15p at least.

It's punters fed up with ph and his perpetual ramping that has done it.

I describe myself except I took a very small profit.

Bought a bottle of wine though.

sww nail on head :)

The sp is moving to match the 0.2p new placing Sareum management did a similar raising yesterday yet got a 40 % increase.
They raised 10% at increased price not a discount.
This level may well hold until some actual news which has been misssing for quite a few months.

OSI Pharma update 6pm tonight, dont miss the webcast